May 28, 2013 - 3:32 pm
5-Alpha reductase inhibitors in patients on active surveillance: Do the benefits outweigh the risk? - Abstract
Published on 24 May 2013
Prostate cancer (PCa) is a slow, progressive disease.
Prostate specific antigen testing, screening, and aggressive case identification has made PCa the most frequently diagnosed cancer. Concerns regarding overdiagnosis and overtreatment flourish on a large scale. In order to avoid overtreatment for those in whom therapeutic intervention is not required, active surveillance for eligible patients with the use of 5-alpha reductase can be considered a safe and a promising approach to delay the progression of the disease with minimal side effects.
Reference: Curr Urol Rep. 2013 Apr 12. Epub ahead of print.